In Suwon, South Korea, a team of scientists has developed a tiny new weapon against cancer — and in lab tests, it wiped out tumors completely.

Professor Yoosoo Yang of Sungkyunkwan University led the research, working with teams from the Korea Institute of Science and Technology and Incheon National University. Together, they created a therapy called EVOTAC, a nanoswitch-based treatment that fights cancer in a clever two-step process.

Here's how it works: Cancer cells send out tiny packages called tumor-derived extracellular vesicles (TEVs) — essentially microscopic bubbles that carry harmful signals and help tumors grow and spread. Current medicines try to block these bubbles entirely, but that causes a problem: the same bubbles can sometimes help the body fight cancer when they're the right kind. Blocking everything reduces the treatment's effectiveness.

EVOTAC solves this by acting like a precision remote control. First, it switches OFF the harmful cancer bubbles by targeting and destroying specific proteins inside tumor cells. Then, doctors apply a gentle laser to the tumor area, which switches ON the production of a different kind of bubble — one that actually trains the immune system to attack cancer. This two-step approach is called "Switching TEVs Off and On."

When the researchers tested EVOTAC on animals with triple-negative breast cancer and colorectal cancer, the results were striking: tumors disappeared completely. Even better, the activated immune response helped prevent the cancer from coming back or spreading to other parts of the body.

Triple-negative breast cancer is one of the hardest types to treat because it lacks the three markers that many modern medicines target. Colorectal cancer is one of the most common cancers worldwide. Finding an effective treatment for either would be significant — for both to be eliminated in animal tests is remarkable.

The findings, published in the journal Signal Transduction and Targeted Therapy, suggest that tumor-derived vesicles don't have to be all bad or all good. They can be redirected, like switching a railway track, to help rather than harm the body.

Researchers say this opens a new direction for cancer treatment. The next step would be testing EVOTAC in more animal studies, with human trials still years away. But for a field that's been searching for smarter, more targeted cancer therapies, this tiny switch represents a big idea — and a reason for genuine hope.